The failure of ALS drug Relyvrio spotlights controversial FDA calls - The Washington Post
washingtonpost.comSubmitted by thewashingtonpost7104 in business
A large clinical trial found that Amylyx Pharmaceuticals’ drug to treat ALS doesn’t work, raising questions about the FDA’s process for approving it.